GlassScriptPhysician profile
James J Gides
NPI 1063487940
$12,772.41
in general payments reported to CMS, 2019-2025
25 companies · $3,329 in 2025
The $3,329 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,801 · 2022: $1,958 · 2023: $2,211 · 2024: $2,474 · 2025: $3,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,961 · Education: $52.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,960.87 |
| Education | $52.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,240.18 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,356.31 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,338.96 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,241.34 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,132.09 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $943.94 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $631.45 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $471.74 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $455.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $386.56 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $303.96 | 2022-2025 | Auvelity |
| Corium, LLC | $279.31 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $220.73 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $129.87 | 2022-2025 | Qelbree |
| Sage Therapeutics, LLC | $111.68 | 2024-2025 | Zurzuvae |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $94.61 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $91.12 | 2022-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.83 | 2024 | |
| Vanda Pharmaceuticals INC. | $82.65 | 2021-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $41.35 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $37.19 | 2021-2023 | Jornay Pm |
| Noven Therapeutics, LLC | $35.20 | 2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $22.67 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.33 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.